摘要
目的研究钙离子拮抗剂苯磺酸氨氯地平缓释片治疗肾性高血压的疗效及安全性。方法将76例确诊为慢性肾功能衰竭肾性高血压患者进行12周的苯磺酸氨氯地平缓释片治疗观察,选取同期60例肾性高血压患者为对照组(采用卡托普利治疗),苯磺酸氨氯地平缓释片起始剂量为5mg,每天2次,最大剂量为10mg,每天2次。卡托普利剂量为25mg,每天3次,检测血压、肾功能、尿蛋白、心率、服药情况及副反应发生情况等。结果治疗12周后,苯磺酸氨氯地平缓释片治疗后血压下降程度分别为(23.00±5.28)/(19.29±2.31)mmHg,总有效率为92.11%(70/76),不良反应发生率为9.21%(7/76);卡托普利治疗后血压下降程度为(11.90±4.18)/(11.80±2.29)mmHg,总有效率为61.67%(37/60),不良反应发生率为16.67%(10/60),两组血压下降程度、总有效率及不良反应发生率差异有显著性(P<0.05)。结论苯磺酸氨氯地平缓释片治疗肾性高血压具有良好的疗效和安全性。
Aim To study the the therapeutic efficacy and safety of amlodipine in the therapy for renal hypertension. Methods 76 patients of renal hypenension with chronic renal failure were diagnosed to be treated with amlodipine for 12 weeks and compared with captopril. The initial dose was 5 mg Q12h, the maximal dose was 10 mg Q12h. the captopril dose was 25 mg Q 8h. The blood pressure, renal function,urea protein,heart rate,administration status and ad- verse reactions of the patients were observed during treating time. Results After 12 weeks of treatment,the blood pressure in amlodipine group was reduced by （23.00 ± 5.28 ） / { 19.29 ± 2.31 ） mmHg. The total effective rate in amlodipine group 92.11% （70/76） respectively. The total adverse incidence rate in amlodipine group was 9.21% （7/76）. While the blood pressure in captopril group was reduced by （ 11.90 ± 4.18 ） / （ 11.80 ± 2.29 ） mmHg. The total effective rate in captopril group was 61.67% （37/60） respectively. The total adverse incidence rate in captopril group were 16. 67% （ 10/60 ）. There were no obvious changes of heart rate and renal function after treatment and no obvious adverse event was showed in amlodipine group. Condusion Amlodipin has a better eficacy and is safe in the therapy of chronic renal failure patients with renal hypertension.
出处
《中国动脉硬化杂志》
CAS
CSCD
北大核心
2009年第7期548-550,共3页
Chinese Journal of Arteriosclerosis
